Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Gavreto: metastatic Non-small cell lung cancer with RET fusion

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test

Broader topic: Non-Small Cell Lung Cancer

Source population
Not part of this definition
Disease extent
metastatic
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
  1. gene
    RET
    alteration
    fusion
    status
    present
prior therapy
    derivation status
    source-attested
    derivation note
    Scoped from the FDA approved indication for Gavreto (pralsetinib) (accelerated-approval table). Only dimensions stated in that wording are part of this definition.
    source wording
    Treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test

    Study evidence for this setting

    4 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

    NCT03037385 · Source cited / selected · Scope: unclear

    Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

    6 outcome links · 4 safety-group records · 0 quality-of-life measures

    →

    NCT03157128 · Source cited / selected · Scope: unclear

    A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

    6 outcome links · 16 safety-group records · 0 quality-of-life measures

    →

    NCT04194944 · Source cited / selected · Scope: unclear

    A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

    6 outcome links · 2 safety-group records · 0 quality-of-life measures

    →

    NCT04222972 · Source cited / selected · Scope: unclear

    A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

    6 outcome links · 3 safety-group records · 0 quality-of-life measures

    →
    Source relationships and population-mapping limitations
    bindings
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice